EUCTR2005-001267-63-AT进行中（未招募）不适用
Bridging study using ch14.18/CHO antibody in children with refractory neuroblastoma
St. Anna Kinderspital0 个研究点目标入组 18 人开始时间: 2005年6月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Inclusion Criteria
- •a.Patients must be £ 21 years of age
- •b.Patients must be diagnosed with neuroblastoma according to the INSS criteria.
- •c.Disease must be considered refractory to conventional therapy including patients
- •-over 1 year of age and presenting as stage 4 disease which have been refractory to first line chemotherapy
- •-over 1 year with recurrent disease after multi-agent chemotherapy (including any stage and biological pattern)
- •-If the patient history meets the above criteria, any disease states except overt progressing disease at the time of antibody treatment renders the patients eligible for this study.
- •d.Patients may not have developed human anti-chimeric antibody due to pre-treatment with ch14.18/SP2/0.
- •e.Patient requirements
- •-Patients must have a performance status greater or equal 70% (Lansky Score, see Appendix I).
- •-Patients must have an estimated life expectancy of at least 12 weeks.
- •-Patients must consent to the placement of a central venous line (Broviac or Hickman catheter), if one has not already been placed, or a stable IV anticipated to last for the 5 days required to administer the 5 infusions each month
- •-Patients must have fully recovered the toxic effects of any prior therapy.
- •-Patients must have no immediate requirements for palliative chemotherapy, radiotherapy or surgery.
- •-Patients may have had prior CNS metastasis providing, the patient’s CNS disease has been previously treated, the patient’s CNS disease has been clinically stable for four weeks prior to starting this study (assessment must be made clinically and by CT or MRI scan), and the patient is off steroids for CNS disease for four weeks prior to starting on study and during the course of the study. Patients with seizure disorders may be enrolled if on anti-convulsants and are well controlled.
- •-Patients should have a shortening fraction of ³ 27% by Echocardiogram or ejection function of >50% by gated radionuclide study.
- •-Patients should have FEV1 and FVC >60% of predicted by pulmonary function tests. Children unable to do PFTs should have no dyspnea at rest and a pulse oximetry >94% on room air.
- •f.Laboratory Testing
- •-All patients must have adequate bone marrow function as defined by ANC >1000/mL, platelets ³75,000/mL and haemoglobin > 9.0 gm/dL. Transfusions are permitted to meet these platelet and haemoglobin criteria.
- •-Patients must have adequate liver function, as defined by an ALT or AST < 5 x normal and a total bilirubin < 1.0 mg/dL.
- •-Patients must have adequate renal function, as defined by a serum creatinin <1.5 mg/dL or a creatinin clearance or radioisotope GFR of > 60 mL/minute.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years)
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Exclusion Criteria
- •a.Patients who have received chemotherapeutic agents (standard or experimental), radiation therapy, or other immunosuppressive therapy within three weeks prior to study.
- •b.Females of childbearing potential will be excluded if they are pregnant, nursing, or not using effective contraception during the treatment period, as the potential effects of ch14.18 on the fetus have not been determined.
- •c.Patients with significant intercurrent illnesses and/or any of the following
- •-Patients with symptoms of congestive heart failure or uncontrolled cardiac rhythm disturbance.
- •-Patients with significant psychiatric disabilities or uncontrolled seizure disorders.
- •-Patients with active infections or active peptic ulcer, unless these conditions are corrected or controlled.
- •-Patients with a clinically significant neurologic deficit or objective peripheral neuropathy (Grade >2) are ineligible.
- •-Patients with clinically significant, symptomatic, pleural effusions.
- •-Patients who require, or are likely to require, corticosteroid or other immunosuppressive drugs for intercurrent disease.
- •-Patients who have had major surgery, i.e. laporotomy or thoracotomy) within the past two weeks.
- •-Patients with organ allografts, including bone marrow or haematopoietic stem cells. Patients receiving prior autologous bone marrow or stem cell reinfusions are eligible.
- •-Patients must be tested for HIV and Hepatitis B Surface (HBS) Ag and excluded, if positive, as this may influence the ability of the immune system to be stimulated by this treatment.
- •d.All patients and/or their parents or legal guardians must sign a written informed consent (Appendix )
- •e.All institutional and national requirements for human studies must be met.
研究者
相似试验
已完成
1 期
ch14.18/CHO Bridging StudyNeuroblastomaNCT01704872St. Anna Kinderkrebsforschung16
进行中（未招募）
不适用
A PHASE I BRIDGING STUDY USING CH14.18/CHO ANTIBODY IN CHILDREN WITH REFRACTORY NEUROBLASTOMA (NB)EUCTR2005-001267-63-ITISTITUTO GIANNINA GASLINI12
进行中（未招募）
1 期
PHASE II STUDY OF CH14.18/CHO IN PATIENTS WITH PRIMARY REFRACTORY OR RELAPSED NEUROBLASTOMAPRIMARY REFRACTORY OR RELAPSED NEUROBLASTOMAMedDRA version: 20.0Level: PTClassification code 10029260Term: NeuroblastomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-000588-42-DEMedical University Greifswald40
进行中（未招募）
1 期
PHASE II STUDY OF CH14.18/CHO IN PATIENTS WITH PRIMARY REFRACTORY OR RELAPSED NEUROBLASTOMAEUCTR2014-000588-42-ATMedical University Greifswald40
Unknown
2 期
Phase II Study of Monoclonal Antibody ch14.18/CHO Continuous Infusion in Patients With Primary Refractory or Relapsed NeuroblastomaNeuroblastomaNCT02743429University Medicine Greifswald40